Stakeholder perspectives on cooperation in the clinical and nonclinical health technology assessment domains

Gina Zimmermann, Sandra Michelmore, Mickael Hiligsmann*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

ObjectivesThe aim of this study was to deliver insights from multiple stakeholders into actual and future collaboration for health technology assessment (HTA) in general and in oncology in particular. MethodsEighteen semi-structured interviews were conducted with experts from European HTA bodies (HTAbs), former board members of the European Network for Health Technology Assessment (EUnetHTA), and representatives from the pharmaceutical industry, a regulatory agency, academia, and patient organizations. The stakeholders were asked about their support of the EUnetHTA's intent, about the general strengths and challenges of the EUnetHTA and its Joint Action 3 (JA 3), the strengths and challenges of the clinically oriented HTA collaboration in oncology during JA 3 across the technology life cycle, about future challenges to HTA in oncology with consequences for collaboration, and about collaboration in the economic domains of HTA. The transcribed interviews were analyzed qualitatively. ResultsThe participants perceived the intention and work quality of the EUnetHTA as positive. The experts described methodological, procedural, and capacity challenges in early dialogues (EDs) and rapid relative effectiveness assessments (REAs) meant to analyze clinical effectiveness in oncology. The majority attached increasing importance to collaboration in the future to cope with the uncertainty of HTA. Several stakeholders also proposed the incorporation of joint postlaunch evidence generation (PLEG) activities. Some gave sporadic suggestions for voluntary nonclinical collaboration as well. ConclusionStakeholders' continued readiness to discuss the remaining challenges to and sufficient resources for implementing HTA regulation, as well as further cooperative expansion along the technology life cycle, are necessary for improved HTA collaboration in Europe.
Original languageEnglish
Article numbere29
Number of pages11
JournalInternational Journal of Technology Assessment in Health Care
Volume39
Issue number1
DOIs
Publication statusPublished - 22 May 2023

Keywords

  • European Union
  • collaboration
  • health technology assessment
  • pharmaceutical technology
  • qualitative
  • EUROPEAN NETWORK
  • EUNETHTA

Fingerprint

Dive into the research topics of 'Stakeholder perspectives on cooperation in the clinical and nonclinical health technology assessment domains'. Together they form a unique fingerprint.

Cite this